Cardiff Oncology, Inc. Q3 FY2023 earnings call

Mark Erlander highlighted that the past quarter was transformational for Cardiff Oncology. Key points include: strong data from the lead program in KRAS-mutated metastatic colorectal cancer, supportive FDA meeting, expansion of partnership with Pfizer, and data release from earlier stage programs in pancreatic cancer and small cell lung cancer with efficacy signals. Objectives to create value include focusing on the lead program in metastatic colorectal cancer, generating data from trials in other indications via capital-efficient investigator-initiated trials, and exploring new therapeutic indications through cost-effective preclinical studies. Accomplishments in the third quarter for the lead program included strong responses in bev naive patients in the second-line trial, preclinical science investigation, FDA meeting leading to moving to first-line development, and partnership with Pfizer Ignite for the CRDF-004 trial.

• Expect to generate data from the first-line CRDF-004 clinical trials in mid-2024. • Continue to generate clinical data from trials in pancreatic cancer, small cell lung cancer, and triple-negative breast cancer in a capital-efficient manner through investigator-initiated trials. • Explore new promising combinations and cancer indications through data-driven, cost-effective preclinical studies.

Q: Mark Frahm asked about PDAC responses and expense trajectory.

A: Mark Erlander said one more patient in the CRDF-001 PDAC trial confirmed a PR, with two remaining patients still on treatment. Jamie Levine discussed that expenses will increase as the first-line colorectal trial ramps up and other investigator-initiated trials start, but net expenses won't significantly increase.

Q: Joe Catanzaro asked about the 004 study's interim data and triggers.

A: Mark Erlander stated they remain confident in having preliminary data mid-2024, working closely with Pfizer Ignite, and the data readout isn't triggered by a specific protocol number but will be based on watching the open-label trial's progress.

Q: Andy Hsieh asked about strategy in trials and IP.

A: Mark Erlander said the strategy of minimizing adverse events from switching between bolus 5-FU and infusional 5-FU is continuing in the trials. On IP strategy, no detailed response provided during the call